Combining Inhibitors of the DNA Damage Response Pathway with Immunotherapies to Treat Cancer

Time: 11:15 am
day: Day One


  • The multiple interfaces between the DDR and the immune response
  • PARP inhibitor immune priming in BRCA deficient cancers
  • The link between ATR inhibition, replication stress and the ability to overcome immunotherapy resistance